Comparative Analysis of Sonication, Microfluidics, and High-Turbulence Microreactors for the Fabrication and Scaling-Up of Diclofenac-Loaded Liposomes
<b>Background</b>: Liposomes are attractive topical carriers, yet translating laboratory fabrication to scalable, well-controlled processes remains challenging. <b>Objectives</b>: We compared three manufacturing methods for diclofenac-loaded liposomes: probe sonication, microfluidic mixing, and a high-turbulence microreactor, under a Quality-by-Design framework. <b>Methods</b>: Differential scanning calorimetry (DSC) was used to define a processing-relevant liquid-crystalline temperature window for the lipid excipients. For sonication scale-up, a Plackett-Burman screening design identified key process factors and supported an energy-density (W·s·L<sup>-1</sup>) control approach. For microfluidics, the effects of flow-rate ratio (FRR) and total flow rate (TFR) were mapped and optimized using a desirability function. Microreactor trials were performed at elevated throughput. Residual ethanol during post-processing was monitored at-line by Raman spectroscopy calibrated against gas chromatography (GC). Particle size and dispersity were measured by DLS and morphology assessed by cryo-TEM. <b>Results</b>: DSC supported a 70-85 °C processing window. Sonication scale-up using an energy-density target (~11,000 W·s·L<sup>-1</sup>) reproduced lab-scale quality at 8 L (Z-average ~87-92 nm; PDI 0.16-0.23; %EE 86-94%). Microfluidics optimization selected FRR 3:1/TFR 4 mL·min<sup>-1</sup>, yielding ~64 nm liposomes with PDI ~0.13 and %EE ~93%. The microreactor achieved ~50 nm liposomes with %EE ~95% at 50 mL·min<sup>-1</sup>. Cryo-TEM corroborated size trends and showed no evident aggregates. <b>Conclusions</b>: All three routes met topical CQAs (~50-100 nm; PDI ≤ 0.30; high %EE). Method selection should be guided by target size/dispersity and operational constraints: sonication enables energy-based scale-up, microfluidics offers precise size control, and microreactors provide higher throughput.
Authors
- Francisco Fernández-Campos (ORCID: https://orcid.org/0000-0001-8224-2932)
- J. Malavia
- Maximilian Schelden
- Nazende Günday-Türeli (ORCID: https://orcid.org/0000-0002-6310-4785)
- Andrés Cruz-Conesa (ORCID: https://orcid.org/0000-0002-1565-0992)
- Maria Lajarin-Reinares (ORCID: https://orcid.org/0000-0002-4080-3516)
- Iria Naveira-Souto (ORCID: https://orcid.org/0009-0000-5026-1311)
- Elisabet Rosell-Vives
- Xavier Julia Camprodon
- Roger Fabrega Alsina
- Eloy Pena-Rodríguez
Institutions
- Reig Jofre (Spain) (ES)
- Institute for Research in Biomedicine (ES)
- Institute for Bioengineering of Catalonia (ES)
- Universitat de Barcelona (ES)
- Ube (Japan) (JP)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2026-01-13
- DOI
- https://doi.org/10.3390/pharmaceutics18010105
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00